Mylan chairman: Teva offers nothing we can't do alone; AbbVie closes $21B Pharmacyclics buy;

@FiercePharma: Regeneus gets green light to move personalized cancer vaccine into PhI. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: AZ, Daiichi sign up Olympian Joyner-Kersee, hoping OIC patients will make tracks to Movantik. FiercePharmaMarketing article | Follow @CarlyHFierce

> Mylan's ($MYL) chairman, Robert Coury, says suitor Teva ($TEVA) offers nothing it can't do on its own. Report

> AbbVie ($ABBV) has closed its $21 billion deal for Pharmacyclics. Report

> The U.S. Supreme Court has declined to hear a case brought by drug companies that didn't want to be forced to pay for collection and disposal of unused drugs, meaning California's Alameda County can now force the pharma industry to do so. More

> Slower FDA approvals negatively impacted full-year 2015 growth for India's Lupin, its CEO said. More

Medical Device News

@FierceMedDev: ICYMI yesterday: SI-Bone raises $21M, brings on new CFO to grow iFuse implant sales. Article | Follow @FierceMedDev

@VarunSaxena2: Pacira's liposomal-encased bupivacaine gets positive reviews at breast cancer conference. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Cancer Genetics strikes genomics deal with Japanese regenerative medicine company. More from FierceDiagnostics | Follow @EmilyWFierce

> CareFusion's Avea ventilator recalled as potentially deadly, FDA says it may cease functioning. Article

> Scientists push back against cancer hereditary genetic tests in NEJM paper. More

> Varian, Flatiron Health to collaborate on oncology electronic health records. Report

Biotech News

@FierceBiotech: UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep. Story | Follow @FierceBiotech

@JohnCFierce: CAR-T powerhouse Juno allies with gene-editing upstart Editas in $737M deal. Article | Follow @JohnCFierce

> Sanofi splurges $245M on Retrophin's speedy-review voucher. Report

> Bluebird widens its CAR-T ambitions with a $130M Five Prime deal. Article

> HIV biotech Calimmune bags $15M to move one-time gene therapy into the clinic. Story

Pharma Marketing News

> My bathtub or yours? How a panned Cialis ad became promotional gold. More

> Revving up for price war with Amgen, Sanofi plots low-cost starter dose of PCSK9 med. Story

> Do doc payments push prescriptions? Study of Medicare scripts suggests it's so. Item

> AZ, Daiichi sign up Olympian Joyner-Kersee, hoping OIC patients will make tracks to Movantik. Article

> Can AZ salvage brodalumab against next-gen psoriasis field? More

Biotech Research News

> Dana-Farber researchers tout a new class of cancer-fighting 'degronimids.' More

> Pitt team unveils two new classes of RNAs for cancer drug R&D. Report

> The White House draws the line against CRISPR/Cas9-designed embryos. Story

> Thunder god vine compound may have potent anti-obesity characteristics. More

> Winship research team flags potential of a new lung cancer therapy. Article

Diagnostics News

> MBio receives $6.3M in support of its portable, optical diagnostic. Story

> Cancer Genetics strikes genomics deal with Japanese regenerative medicine company. Item

> Quest Diagnostics shares hit record high amid takeover rumors. Report

> Roche gets FDA green light for quick C. difficile test. Article

> Sequenom stares down suit from Indian genomics firm. More

And Finally... Novartis ($NVS) is betting on a so-called robotic pill from startup Rani Therapeutics. More (sub. req.)

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.